We provide top-quality generic anticancer drugs, specialty oncology products and other injectable products to both regulated and emerging markets.
We offer a wide range of services from developmental to scale-up to manufacturing of clinical and commercial lots either in pre-filled syringes, solution or lyophilized vials. Uman Pharma's strength is in its versatility and its capacity to handle cytotoxic and highly potent compounds.
Our 130 000 sq. ft complex has two manufacturing units: one unit is dedicated to the manufacturing of sterile injectable products while the other is used for visual inspection and packaging. In addition, Uman Pharma can count on approximately twenty laboratories equipped for research & development, product formulation and quality control.
June 4, 2013
Uman Pharma is pleased to announce that it has successfully passed its inspection by the United States Food and Drug Administration (FDA).... > Read more
November 9, 2011
Uman Pharma Inc., a Canadian privately owned generic pharmaceutical company is pleased to announce the conclusion of a strategic partnership with CFR Pharmaceuticals S. A. (CFR) of Santiago, Chile.... > Read more
April 27, 2010
Under the terms of the agreement, Antares and Uman will invest jointly to develop and commercialize VIBEXTM MTX, Antares' novel pressure-assisted injection device, containing methotrexate for rheumatoid arthritis and related autoimmune conditions in the US and Canada.... > Read more
April 14, 2009
Uman Pharma is proud to announce the receipt of the Establishment Licence from Health Canada for the production and packaging of sterile and solid oral dosage pharmaceutical products.... > Read more
October 23, 2008
Uman Pharma is offering the newly generic EPIRUBICIN drug in Canada.... > Read more
May 1, 2008
Uman Pharma is proud to announce the acquisition of the Bristol Myers-Squibb facility in Candiac (Canada).... > Read more